The Practical Cardiology™ Antithrombotic Therapy clinical resource center offers updates and information about the latest in the fields of antiplatelet and anticoagulation therapy. On this page you will find content related to FDA approvals and the latest information for preventing thrombosis in the form of articles, video interviews with leading experts, clinician-authored columns, and more.
August 29, 2022
The PANTHER study, which was a meta-analysis of 7 RCTs comparing P2Y12 inhibitor monotherapy against aspirin for secondary prevention in CAD, suggests use of P2Y12 inhibitor monotherapy was associated with a 12% reduction in risk of the primary composite endpoint, with a 23% relative reduction in risk of myocardial infarction.
August 28, 2022
A phase 2 dose-finding trial presented at ESC Congress 22 suggests the use of milvexian could reduce the risk of ischemic stroke by up to 30% without a major increase in the risk of bleeding events in certain doses.
August 12, 2022
On August 11, the American College of Chest Physicians (CHEST) released 44 new evidence-based recommendations in their new guidelines for perioperative management of antithrombotic therapy, which were published with the intention of replacing the 2012 guidelines on the subject.
July 15, 2022
After US-based data suggested cost as an inhibiting factor of ticagrelor use in older patients with ACS, an analysis of use in Canada details considerable variation in between-hospital levels of ticargelor, with use ranging from 0% to 83.6% of patients.
June 27, 2022
Dr. Gregory Weiss provides perspective on a recent study detailing the risks of thrombosis observed with different COVID-19 vaccines among patients from a group of countries in Europe.
June 16, 2022
A secondary analysis of the AFIRE trial provides further detail on the reduction in event risk and mortality associated with rivaroxaban monotherapy compared to combination therapy in patients with atrial fibrillation and stable coronary artery disease.
May 25, 2022
A post hoc analysis of the AUGUSTUS trial provides an overview of the effects of various antithrombotic regimens after ACS or PCI in patients with AFib and a history of stroke, TIA, or thromboembolism.
May 20, 2022
An analysis of data from the Fuwai PCI registry details the incidence of adverse events and risk of bleeding associated with clopidogrel monotherapy versus aspirin monotherapy 12 months post-PCI in high-risk patients.
April 06, 2022
Data from a phase 2b trial of bentracimab presented by Deepak Bhatt, MD, MPH, at ACC.22 demonstrates it the ability for reversing antiplatelet effects in an older population.